Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0361 | 0.5 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0361 | 0.5 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0361 | 0.5 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0361 | 0.5 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0361 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0361 | 0.5 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0361 | 0.5 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0361 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 5.66 % | Neurotoxicity in Swiss albino CF1 mouse assessed as decrease in locomotor activity at 30 mg/kg, ip after 0.5 hrs postdose | ChEMBL. | 21930331 |
Activity (ADMET) | = 66.5 % | Neurotoxicity in Swiss albino CF1 mouse assessed as decrease in locomotor activity at 30 mg/kg, ip after 4 hrs postdose | ChEMBL. | 21930331 |
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed Swiss albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs | ChEMBL. | 21930331 |
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed Swiss albino CF1 mouse assessed as protection against maximal electroshock-induced seizures after 4 hrs | ChEMBL. | 21930331 |
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed Swiss albino CF1 mouse assessed as protection against maximal electroshock-induced seizures after 0.5 hrs | ChEMBL. | 21930331 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.